Erdafitinib is a tyrosine kinase inhibitor of fibroblast growth factor receptor 1 through 4 and was approved by the US Food and Drug Administration earlier this year as a second-line treatment for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations.
First oral drug for advanced or metastatic bladder cancer.
A new study found a biopsy of a single metastasis may be enough to help oncologists tailor a treatment that targets all of a patient’s tumors.
A new agent that targets Nectin-4, a protein found in 97% of urothelial cancers, may be an option for patients with locally advanced or metastatic forms of urothelial cancer.
Dr. Balar highlights promising evidence on the potential benefits of the use of immunotherapy in the advanced bladder cancer setting.
Erdafitinib is first targeted therapy for FGFR3 or FGFR2 genetic alteration.
The updates to the guidelines reflect recent advances, including recommended immunotherapies and changes in tumor staging.
Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.
In this review, we discuss known data and the differences between the different immune checkpoint inhibitors, as well as future avenues to explore with immuno-oncologic agents in urothelial cancer.
Several factors, including race, insurance, and type of facility, were associated with delays in neoadjuvant chemotherapy treatment for bladder cancer patients.